Pills have served biopharma pretty well over the years. Easy to design and cheap to produce, the so-called small-molecule therapies that fit in a capsule have made billions of dollars for their inventors and treated millions of patients in the process.
Now, however, as yesteryear’s swallowable blockbusters go generic, the industry is running into diseases for which pills can find no quarter.
About the Author Reprints
Boston Globe – This is a huge “bait and switch”! I pay for my subscription to the Globe and when I click on the first article in the business section, you tell me you want more money!?! This leaves a really bad taste in my mouth.